110
Participants
Start Date
March 15, 2023
Primary Completion Date
September 15, 2026
Study Completion Date
December 31, 2026
GEN1160
IV infusion of GEN1160
RECRUITING
NYU Langone Health, New York
ACTIVE_NOT_RECRUITING
Montefiore Medical Center - Montefiore Hospital, The Bronx
ACTIVE_NOT_RECRUITING
Levine Cancer Center, Charlotte
RECRUITING
Sarah Cannon Research Institute - Nashville, Nashville
ACTIVE_NOT_RECRUITING
Cleveland Clinic - Euclid Hospital, Cleveland
ACTIVE_NOT_RECRUITING
University of Michigan, Ann Arbor
COMPLETED
Karmanos Cancer Institute, Detroit
COMPLETED
Washington University School of Medicine in St. Louis, St Louis
ACTIVE_NOT_RECRUITING
MD Anderson Cancer Center, Houston
ACTIVE_NOT_RECRUITING
START Mountain Cancer Center, West Valley City
RECRUITING
City of Hope Comprehensive Cancer Center - Duarte, Duarte
RECRUITING
The City of Hope Orange County Lennar Foundation Cancer Center, Irvine
ACTIVE_NOT_RECRUITING
Providence Portland Medical Center, Portland
RECRUITING
Oregon Health & Science University, Portland
ACTIVE_NOT_RECRUITING
Cancer Hospital of Chinese Academy of Medical Sciences, Beijing
ACTIVE_NOT_RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
ACTIVE_NOT_RECRUITING
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai
Lead Sponsor
Genmab
INDUSTRY